'Preimplantation Genetic Diagnosis 2018: Current Practice and Beyond', 9-10 November 2018
Page URL: https://www.bionews.org.uk/page_94943

Review: Panorama – Can You Cure My Cancer?

2 March 2015
Appeared in BioNews 792

Last month, we learned that one in two of us will be diagnosed with cancer at some point in our lives. With that dramatic statistic in mind, this hour-long Panorama documentary was well-timed as it details how innovative treatments are being developed at the Institute of Cancer Research and trialled at the Royal Marsden (both websites have extensive details on the treatments and trials featured on the programme). 

The programme was shot over a time period of two years and shows how the two institutions are working together to bring groundbreaking therapies from bench to bedside. The trials are testing immunotherapy, chosen by Science as breakthrough of the year back in 2013. 

The treatments offer new prospects for people for whom the traditional three options (surgery, radiation, and chemotherapy) have not worked. Throughout the programme, patients with a range of cancers tell their stories: how they were told they only had months to live, and how that was (in some cases) years ago. 

However, it is clear these are not wonder drugs. At the moment, the treatments only work for a small group of patients with very specific types of cancer, and very specific tumour mutations. And even then, the treatment does not always work in the long-term: it extends their lives but the tumours eventually evolve and develop resistance against these new drugs as well.

It's not all doom and gloom though. The patients themselves are positive: the drugs do not just buy them time, they give back quality of life as well. One of the main benefits of immunotherapies seems to be their relatively mild side effects compared to treatments like chemotherapy. While chemo targets all fast dividing cells, inevitably also affecting some healthy cells, immunotherapy is much more specific to cancer cells. Some inconveniences related to the treatments, such as having to avoid sunlight due to photosensitivity, may be offset by other benefits, like being able to take the drugs at home.

One important aspect appears to have been glossed over in this programme though: the price of the drugs. Last month, scientists from the University of York criticised the Cancer Drugs Fund, from which these drugs would be paid for, as being 'poor value' and argued it diverts funds from other patient services. As the therapies shown on the programme show their worth and move into daily practice, this will become an important factor.

Overall, the documentary shows a story of hope for a future where doctors and scientists will be able to target even more tumour types and anticipate drug resistance. It shows innovation happening right here in our NHS, without the need for the Medical Innovation, or Saatchi, Bill using trials that will provide evidence to benefit patients over years to come. 

SOURCES & REFERENCES
BBC iPlayer - Panorama
BBC |  11 February 2015
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
16 February 2015 - by Dr Nicoletta Charolidi 
The order in which mutations occur in a cell can determine the clinical outcome of certain cancers, according to research published in the New England Journal of Medicine...
19 May 2014 - by Antony Blackburn-Starza 
British pharmaceutical company AstraZeneca has presented trial data from an experimental lung cancer drug...
19 August 2013 - by Siobhan Chan 
Human stem cells have been reprogrammed to form cancer-targeting immune cells that were shown to stop tumour growth in mice...
25 March 2013 - by John Brinsley 
Early results of an experimental gene therapy against an aggressive form of leukaemia have been hailed by researchers as showing 'life saving potential'....
7 January 2013 - by Dr Greg Ball 
Immune cells that can recognise and kill cancer cells have been grown from induced pluripotent stem cells (iPSCs)...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.